A sale or merger are possible options for the IT business. McKesson is looking to divest its IT business — called Technology Solutions — in order to focus its efforts on its drug distribution business,according to The...
McKesson Looking To Divest Its IT Unit To Focus On Drug Distribution
A sale or merger are possible options for the IT business. McKesson is looking to divest its IT business — called Technology Solutions — in order to focus its efforts on its drug distribution business,according to The...
Impax to Buy Allergan, Teva Drug Portfolio for $586 Million
Impax Laboratories Inc. will buy a portfolio of drugs from Teva Pharmaceutical Industries Ltd. and Allergan Plc for $586 million as the two larger pharmaceutical companies divest products to gain antitrust approval for...
FDI in pharma to boost M&A deals, private equity investments
The pharmaceutical sector in India will register higher growth during the course of the next five years (22%) as compared to a CAGR of about 14% clocked by the sector during 2010-14, a report said. The government’s...
China rolls out sops for investments to Indian pharma companies
MUMBAI: China, the second largest pharmaceutical market in the world after US, is luring Indian drug companies to set up greenfield operations in that country. To roll out the red carpet, the local government has...
Aurobindo Pharma to acquire group firm Trident Life Sciences for Rs 135 cr
The Rs 2,800-crore Aurobindo Pharma Ltd (APL) will buy out its group company — Trident Life Sciences Ltd (TLSL), a clinical research organisation (CRO) – for about Rs 135 crore. The board of directors of the...
Aurobindo Pharma to acquire Trident Life Sciences
Drug manufacturer Aurobindo Pharma today said it will acquire Trident Life Sciences (TLSL) for an undisclosed amount. The board has approved the acquisition of 100 per cent stake of TLSL...
SAT stops Zenotech open offer
Japanese drug maker Daiichi Sankyo’s open offer that was to open tomorrow to mop up an additional 20 per cent of Zenotech Laboratories, Hyderabad, has hit yet another hurdle. This time, it is the Securities...
Daiichi to book $3.86 bn loss to buy Ranbaxy
Daiichi to book $3.86 bn loss to buy Ranbaxy Japanese drug major Daiichi Sankyo, which acquired 63.92 per cent stake in Ranbaxy for $4.6 billion (around Rs 23,000 crore), said that the transaction would result in a...
Sun raises offer 23% for Taro s residual stake
Sun raises offer 23% for Taro s residual stake Sun Pharmaceuticals raised its offer by as much as 23 per cent to buy the residual stake of Taro Pharmaceutical Industries in a bid to gain a controlling stake in the...
No reconciliation in sight for Sun-Taro row
No reconciliation in sight for Sun-Taro row All chances of an out-of court settlement between Sun Pharma and Israeli drug-maker Taro Pharma seem to be diminishing, with even reconciliatory efforts ending in...
Taro demands $15/share for merger with Sun
Taro demands $15/share for merger with Sun Israeli drug major Taro Pharmaceutical, which is battling a hostile takeover bid, has demanded a 58 per cent premium, or $15 per share, in cash to effect a merger with Sun...
